[1]闵 松,黄林娜.缬沙坦联合氨氯地平治疗高血压合并糖尿病患者的疗效及对其糖脂代谢水平的影响[J].医学信息,2025,38(03):134-137.[doi:10.3969/j.issn.1006-1959.2025.03.026]
　MIN Song,HUANG Linna.Efficacy of Valsartan Combined with Amlodipine in the Treatment of Patients with Hypertension and Diabetes Mellitus and its Effect on Glucose and Lipid Metabolism[J].Journal of Medical Information,2025,38(03):134-137.[doi:10.3969/j.issn.1006-1959.2025.03.026]
点击复制

缬沙坦联合氨氯地平治疗高血压合并糖尿病患者的疗效及对其糖脂代谢水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年03期
页码:
134-137
栏目:
论著
出版日期:
2025-02-01

文章信息/Info

Title:
Efficacy of Valsartan Combined with Amlodipine in the Treatment of Patients with Hypertension and Diabetes Mellitus and its Effect on Glucose and Lipid Metabolism
文章编号:
1006-1959（2025）03-0134-04
作者:
闵 松; 黄林娜
西安市高陵区中医医院内分泌科，陕西 西安 710200
Author(s):
MIN Song;  HUANG Linna
Department of Endocrinology, Gaoling District Hospital of Traditional Chinese Medicine, Xi′an 710200, Shaanxi, China
关键词:
缬沙坦; 氨氯地平; 高血压; 糖尿病; 血脂异常; 糖脂代谢水平
Keywords:
Valsartan;  Amlodipine;  Hypertension;  Diabetes mellitus;  Dyslipidemia;  Glucose and lipid metabolism level
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2025.03.026
文献标志码:
A
摘要:
目的 观察缬沙坦联合氨氯地平治疗高血压合并糖尿病患者的疗效及对其糖脂代谢水平的影响。方法 采用随机数字表法将2023年1月-2024年1月我院接诊的72例高血压合并糖尿病患者分为对照组（n=36）和观察组（n=36）。对照组应用氨氯地平治疗，观察组在对照组基础上联合应用缬沙坦治疗，比较两组临床疗效、血压水平、血糖水平、血脂指标及临床不良反应发生率。结果 与对照组治疗总有效率的83.33%比较，观察组治疗总有效率更高，达94.44%（P＜0.05）；与同组治疗前比较，两组治疗后收缩压、舒张压降低，且与对照组比较，观察组收缩压、舒张压更低（P＜0.05）；与同组治疗前比较，两组治疗后空腹血糖、餐后2 h血糖水平降低，且与对照组比较，观察组空腹血糖、餐后2 h血糖水平更低（P＜0.05）；与同组治疗前比较，两组治疗后总胆固醇、三酰甘油、低密度脂蛋白胆固醇水平降低，且与对照组比较，观察组总胆固醇、三酰甘油、低密度脂蛋白胆固醇水平更低（P＜0.05）；观察组不良反应总发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 缬沙坦联合氨氯地平治疗可提高高血压合并糖尿病患者治疗效果，改善血糖、血脂、血压水平，且不会增加不良反应发生率，是一种可行、有效的联合用药治疗方案。
Abstract:
Objective To observe the efficacy of valsartan combined with amlodipine in the treatment of patients with hypertension and diabetes mellitus and its effect on glucose and lipid metabolism. Methods Using the random number table method, totally 72 patients with hypertension and diabetes mellitus who were admitted to our hospital from January 2023 to January 2024 , and divided into control group (n=36) and observation group (n=36). In the control group, patients were treated with amlodipine, while in the observation group, patients were treated with valsartan on the basis of the control group. The clinical efficacy, blood pressure level, blood glucose level, blood lipid index and the incidence of clinical adverse reactions were compared between the two groups. Results Compared with 83.33 % of the total effective rate of the control group, the total effective rate of the observation group was higher, reaching 94.44% (P<0.05). Compared with the same group before treatment, the systolic blood pressure and diastolic blood pressure of the two groups were decreased after treatment, and compared with the control group, the systolic blood pressure and diastolic blood pressure of the observation group were lower (P<0.05). Compared with the same group before treatment, the levels of fasting blood glucose and 2 h postprandial blood glucose in the two groups were decreased after treatment, and compared with the control group, the levels of fasting blood glucose and 2 h postprandial blood glucose in the observation group were lower (P<0.05). Compared with the same group before treatment, the levels of total cholesterol, triglyceride and low density lipoprotein cholesterol in the two groups were decreased after treatment, and compared with the control group, the levels of total cholesterol, triglyceride and low density lipoprotein cholesterol in the observation group were lower (P<0.05). There was no significant difference in the total incidence of adverse reactions between the observation group and the control group (P>0.05). Conclusion Valsartan combined with amlodipine can improve the therapeutic effect of patients with hypertension and diabetes mellitus, improve blood glucose, blood lipid and blood pressure levels, and will not increase the incidence of adverse reactions. It is a feasible and effective combination therapy.

参考文献/References:

[1]乔震.缬沙坦联合氨氯地平治疗社区老年原发性高血压合并糖尿病的疗效分析[J].现代诊断与治疗,2020,31(3):380-382.[2]杜清碎.缬沙坦联合氨氯地平治疗社区老年原发性高血压合并糖尿病的疗效[J].吉林医学,2020,41(4):863-865.[3]俞惠琴.缬沙坦联合氨氯地平治疗社区老年原发性高血压合并糖尿病疗效[J].山西医药杂志,2020,49(22):3110-3112.[4]吴艳.缬沙坦联合氨氯地平对社区老年原发性高血压合并糖尿病的治疗作用分析[J].黑龙江医药,2019,32(4):814-816.[5]郑伟.厄贝沙坦联合苯磺酸氨氯地平治疗老年糖尿病高血压合并高尿酸血症患者的临床疗效[J].中国医药科学,2020,10(8):66-69.[6]钟达宏,刘子胥,石琼梅.缬沙坦和氨氯地平在社区老年原发高血压合并糖尿病中的应用观察[J].中国医药科学,2016,6(8):68-70.[7]Tian S,Li Z,Xiao DS,et al.Expert consensus on management of metabolic disease in Chinese liver transplant recipients[J].World Journal of Gastroenterology,2020,26(27):3851-3864.[8]周觅.缬沙坦联合氨氯地平治疗社区老年原发性高血压病合并糖尿病的效果研究[J].中国全科医学,2021,24(2):111-114.[9]王学坤,云璐,董瑜等.西尼地平与氨氯地平联合缬沙坦对老年原发性高血压伴左心室肥厚患者影响的对比研究[J].实用心脑肺血管病杂志,2018,26(10):66-69[10]王世勋,王娟玲,刘同祥.缬沙坦和氨氯地平对高血压病患者血浆Apelin-12水平影响的对比性研究[J].中国临床实用医学,2010,4(12):74-75.[11]刘艳,王晓明,葛伟.缬沙坦氨氯地平治疗老年高血压的依性及药物经济学优势[J].中国老年学杂志,2017,37(5):1148-1149.[12]张豫.瑞格列奈分别联合氨氯地平、氯沙坦钾治疗2型糖尿病合并原发性高血压的临床研究[J].吉林药学,2018,11(3):146-147.[13]韦立.缬沙坦联合氨氯地平对老年高血压合并 2 型糖尿病患者血压、血糖和血尿酸水平的影响[J].河南医学研究,2018,27(20):3781-3782.[14]黄经.氨氯地平联合缬沙坦对老年原发性高血压合并糖尿病患者胰岛功能、肾功能的影响[J].慢性病学杂志,2018,19(11):1526-1528,1531．[15]徐丹,黄龙贤,周大燕,等.瑞格列奈分别联合氨氯地平、氯沙坦钾治疗T2DM合并原发性高血压的疗效和安全性比较[J].中国药房,2017,28(3):327-330.[16]喻俊颜,何光亮.老年原发性高血压应用氨氯地平联合缬沙坦治疗的临床研究[J].四川医学,2018,39(6):693-694.[17]郭山岭.奥美沙坦联合氨氯地平治疗高血压并发糖尿病患者的疗效及其对血管内皮功能、血压变异性的影响[J].新乡医学院学报,2018,35(8):701-704.[18]王琦,姚炯.缬沙坦联合氨氯地平治疗社区老年人原发性高血压合并糖尿病疗效观察[J].中国基层医药,2016,23(3):321-324.[19]曹甜甜,徐海丽,贺延,等.缬沙坦和氨氯地平联合应用治疗老年高血压临床疗效[J].武警医学,2016,27(12):1225-1227,1230.

相似文献/References:

[1]乔 君,高 翔,王 瑜,等.缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响[J].医学信息,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
　QIAO Jun,GAO Xiang,WANG Yu,et al.The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension[J].Journal of Medical Information,2018,31(03):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
[2]张莉莉.左旋氨氯地平和氨氯地平治疗轻中度高血压临床效果观察[J].医学信息,2018,31(21):149.[doi:10.3969/j.issn.1006-1959.2018.21.043]
　ZHANG Li-li.Clinical Efficacy of Levamlodipine and Amlodipine in Treatment of Mild to Moderate Hypertension[J].Journal of Medical Information,2018,31(03):149.[doi:10.3969/j.issn.1006-1959.2018.21.043]
[3]高占群,李 霜,刘 杨.立普妥与瑞舒伐他汀联合缬沙坦治疗糖尿病 并发心力衰竭的临床疗效[J].医学信息,2019,32(15):140.[doi:10.3969/j.issn.1006-1959.2019.15.045]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Efficacy of Lipitor and Rosuvastatin Combined with Valsartan in the Treatment of Diabetes Complicated with Heart Failure[J].Journal of Medical Information,2019,32(03):140.[doi:10.3969/j.issn.1006-1959.2019.15.045]
[4]田云朋,卢成志,赵向东.缬沙坦治疗慢性心功能不全合并阵发性房颤的临床疗效[J].医学信息,2019,32(13):135.[doi:10.3969/j.issn.1006-1959.2019.13.041]
　TIAN Yun-peng,LU Cheng-zhi,ZHAO Xiang-dong.Clinical Efficacy of Valsartan in the Treatment of Chronic Heart Failure Complicated with Paroxysmal Atrial Fibrillation[J].Journal of Medical Information,2019,32(03):135.[doi:10.3969/j.issn.1006-1959.2019.13.041]
[5]王 力,袁志强,黄晓鹏,等.前列地尔联合缬沙坦对慢性肾小球肾炎患者肾功能指标的影响[J].医学信息,2019,32(21):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
　WANG Li,YUAN Zhi-qiang,HUANG Xiao-peng,et al.Effect of Alprostadil Combined with Valsartan on Renal Function Indexes in Patients with Chronic Glomerulonephritis[J].Journal of Medical Information,2019,32(03):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
[6]孔令玲.参芪地黄汤联合缬沙坦治疗气阴两虚型早期糖尿病肾病的疗效[J].医学信息,2020,33(02):160.[doi:10.3969/j.issn.1006-1959.2020.02.050]
　KONG Ling-ling.Efficacy of Shenqi Dihuang Decoction Combined with Valsartan in the Treatment of Early Diabetic Nephropathy with Deficiency of Qi and Yin[J].Journal of Medical Information,2020,33(03):160.[doi:10.3969/j.issn.1006-1959.2020.02.050]
[7]陈钰泱,石爱杰.缬沙坦联合前列地尔治疗慢性肾小球肾炎的效果[J].医学信息,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
　CHEN Yu-yang,SHI Ai-jie.The Effect of Valsartan Combined with Alprostadil on Chronic Glomerulonephritis[J].Journal of Medical Information,2020,33(03):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
[8]张成杰,安庆华,郑玉明,等.苯磺酸左旋氨氯地平与缬沙坦对高血压患者脂质代谢和系统性应激的影响[J].医学信息,2020,33(21):140.[doi:10.3969/j.issn.1006-1959.2020.21.043]
　ZHANG Cheng-jie,AN Qing-hua,ZHENG Yu-ming,et al.Effects of Levamlodipine Besylateand Valsartan on Lipid Metabolism and Systemic Stress in Patients with Hypertension[J].Journal of Medical Information,2020,33(03):140.[doi:10.3969/j.issn.1006-1959.2020.21.043]
[9]范卢明,王 慧,薛 帆,等.缬沙坦联合二甲双胍治疗肥胖型高血压效果的Meta分析[J].医学信息,2022,35(15):68.[doi:10.3969/j.issn.1006-1959.2022.15.014]
　FAN Lu-ming,WANG Hui,XUE Fan,et al.Meta-analysis of the Effect of Valsartan Combined with Metformin in the Treatment of Obese Hypertension[J].Journal of Medical Information,2022,35(03):68.[doi:10.3969/j.issn.1006-1959.2022.15.014]

更新日期/Last Update: 1900-01-01